MedTrace Logo

Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386

NCT00690079 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2010-12-10

No results posted yet for this study

Summary

The study is being performed in order to learn more about the safety and tolerability of AZD1386. AZD1386 is primary intended for treatment of chronic pain.

Conditions

Interventions

DRUG

AZD1386

Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L

DRUG

Placebo

Oral admin. of doses at 11 days through a 12 days period.

Sponsors & Collaborators

Principal Investigators

  • Rolf Karlsten · Emerging Analgesia TA AstraZeneca R&D Södertälje, Sweden

  • Ray Chetty · AstraZeneca Alderly Park1G61 Mereside, Alderly Park, Macclesfeld, Cheshire, England SK104TG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00690079 on ClinicalTrials.gov